We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
KL1333 is a drug intended for treatment of orphan genetic mitochondrial disorders and the in-licensed project is about to enter Phase I clinical development.